FDA authorized Memorial Sloan Kettering Cancer Center’s Integrated Mutation Profiling of Actionable Cancer Targets tumor profiling test, an in vitro diagnostic test that can identify a higher number of genetic mutations that may be found in various cancers than any test previously reviewed by the agency.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
